iPiE – Intelligence-led Assessment of Pharmaceuticals in the Environment

Leading organisations:
Innovative Medicines Initiative - IMI

Timeframe:
2015-2019

Geographic Area:
Pan-European

Objectives:

To develop a framework that will provide methodologies to prioritise new and existing medicinal compounds for a comprehensive environmental risk assessment.


Target audience:
Pharmaceutical manufacturers and Scientists

Area of interest:
Occurrence of pharmaceuticals in the environment and Pharmaceutical manufacturing

Activities:

1) To review of existing approaches for prioritization of APIs and their intelligent testing based on mode of action and to develop improved frameworks for such purposes, 2) To establish a high-quality database on the properties, environmental fate characteristics and ecotoxicity of APIs, 3) To develop methods for estimating external and internal exposure to APIs for different scenarios, 4) To develop methods and models for predicting ecotoxicological responses to APIs, 5) To validate the developed models, concepts and frameworks using targeted experiments, 6) To develop a software system to support intelligent testing and prioritization of APIs in the environment, 7) To develop guidance on how the software system and associated predictive tools can be used, 8) To engage with and exchange knowledge with stakeholder groups throughout the project.


Communication material:

Return to search form.

HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.